The Evolution of Interferon-alpha as Therapy for Patients with Polycythemia Vera and Essential Thrombocythemia was recorded during the 2015 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress held in Alexandria, VA, August 28-29, 2015. The symposium highlights risk assessment criteria, guidelines for initiation of cytoreductive therapy, and the utilization and development of interferon-alpha in the therapy of PV and ET for the enhancement of clinical outcomes and patient quality of life.
In this presentation, Dr. Elizabeth O. Hexner discusses the difference between long-acting interferon and existing formulations.
Earn accreditation for this activity at the following location:
© 2015 Imedex, LLC.